SANA vs SLDB
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
SANA · Sana Biotechnology$2.37 ▲ 1.28%
SLDB · Solid Biosciences$6.59 ▲ 6.63%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- SANA -42.5%
- SLDB +58.8%
Head to head
| Metric | SANA | SLDB |
|---|---|---|
| Price | $2.37 | $6.59 |
| Change today | ▲ 1.28% | ▲ 6.63% |
| Market cap | $710.13M | $735.51M |
| Return, 3 months | -34.3% | -23.0% |
| Return, year to date | -41.8% | +16.8% |
| Return, 1 year | -42.1% | +62.3% |
| P/E (TTM) | -4.6 | -3.7 |
| P/B | 3.9 | 2.2 |
| P/E percentile vs own 5y | 57th | 12th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | – |
| Net profit growth (YoY) | +32.2% | -38.8% |
| Gross margin | – | – |
| Operating margin | – | – |
| Net margin | – | – |
| Return on equity | -152.9% | -65.5% |
| Analyst target vs. price | +237.6% | +203.5% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 42 | 50 |
| 30-day volatility | 67.2% | 75.0% |
| Max drawdown, 1 year | -59.4% | -51.0% |
| Trend read | Strong downtrend | Leaning bullish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- SLDB is the largest of the group by market value.
- SLDB has returned the most over the past year.
- SANA carries the lowest trailing P/E.
- SANA has been the calmest stock over the last 30 days.